CA2922143C - Repertoire de transcriptome pour la caracterisation de reponse de reparation cellulaire apres blessure des tissus mous dans des articulations synoviales - Google Patents

Repertoire de transcriptome pour la caracterisation de reponse de reparation cellulaire apres blessure des tissus mous dans des articulations synoviales Download PDF

Info

Publication number
CA2922143C
CA2922143C CA2922143A CA2922143A CA2922143C CA 2922143 C CA2922143 C CA 2922143C CA 2922143 A CA2922143 A CA 2922143A CA 2922143 A CA2922143 A CA 2922143A CA 2922143 C CA2922143 C CA 2922143C
Authority
CA
Canada
Prior art keywords
interleukin
ligand
factor
chemokine
motif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2922143A
Other languages
English (en)
Other versions
CA2922143A1 (fr
Inventor
Deva CHAN
Jun Li
Anna H.K. Plaas
John D. Sandy
Vincent Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rush University Medical Center
Original Assignee
Rush University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush University Medical Center filed Critical Rush University Medical Center
Publication of CA2922143A1 publication Critical patent/CA2922143A1/fr
Application granted granted Critical
Publication of CA2922143C publication Critical patent/CA2922143C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon un aspect, la présente invention concerne des procédés pour la classification de la qualité d'une réponse de réparation après blessure à une articulation d'un sujet. Selon un mode de réalisation, le procédé comprend l'utilisation d'un échantillon tissulaire prélevé depuis la région blessée de l'articulation et la détermination des niveaux d'expression dans l'échantillon d'une pluralité de gènes, comprenant au moins ces gènes répertoriés dans le tableau 1, le tableau 2 et le tableau 3. Selon un autre aspect, l'invention concerne des procédés de traitement d'un sujet humain ou animal atteint d'une blessure à une articulation sur la base de la classification de la qualité de réponse de réparation.
CA2922143A 2013-09-12 2014-09-08 Repertoire de transcriptome pour la caracterisation de reponse de reparation cellulaire apres blessure des tissus mous dans des articulations synoviales Active CA2922143C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361877011P 2013-09-12 2013-09-12
US61/877,011 2013-09-12
PCT/US2014/054550 WO2015038474A1 (fr) 2013-09-12 2014-09-08 Répertoire de transcriptome pour la caractérisation de réponse de réparation cellulaire après blessure des tissus mous dans des articulations synoviales

Publications (2)

Publication Number Publication Date
CA2922143A1 CA2922143A1 (fr) 2015-03-19
CA2922143C true CA2922143C (fr) 2022-03-08

Family

ID=52666189

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2922143A Active CA2922143C (fr) 2013-09-12 2014-09-08 Repertoire de transcriptome pour la caracterisation de reponse de reparation cellulaire apres blessure des tissus mous dans des articulations synoviales

Country Status (6)

Country Link
US (2) US9994903B2 (fr)
EP (1) EP3044336B1 (fr)
CN (1) CN105531378B (fr)
CA (1) CA2922143C (fr)
ES (1) ES2756173T3 (fr)
WO (1) WO2015038474A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922143C (fr) 2013-09-12 2022-03-08 Rush University Medical Center Repertoire de transcriptome pour la caracterisation de reponse de reparation cellulaire apres blessure des tissus mous dans des articulations synoviales
WO2016205259A1 (fr) * 2015-06-14 2016-12-22 Hoke Glenn Dale Procédés de diagnostic et de traitement de plaies
US20190093166A1 (en) * 2016-03-04 2019-03-28 Rush University Medical Center Methods for characterizing the cellular repair response after soft tissue injury
CA3201466A1 (fr) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methodes de traitement de troubles metaboliques et de maladies cardiovasculaires avec des inhibiteurs de la sous-unite beta e de l'inhibine (inhbe)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2334075A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Proteine morphogenetique osseuse
JP2004536575A (ja) * 2001-02-28 2004-12-09 コンドロジーン・インコーポレイテッド 変形性関節症に関連する組成物および方法
DE10127572A1 (de) 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
CN103497993A (zh) * 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
US20090068656A1 (en) * 2006-10-02 2009-03-12 Frank Beier Methods of diagnosing osteoarthritis
EP2304052A2 (fr) 2008-05-02 2011-04-06 Interleukin Genetics, Inc. Détection d'une prédisposition génétique à des états associés à l'ostéoarthrite
ES2351456B1 (es) 2009-06-24 2011-11-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b
WO2012037356A2 (fr) * 2010-09-15 2012-03-22 Rush University Medical Center Profils et produits d'expression génique pour le diagnostic et le pronostic de la synovite et l'ostéoarthrite post-lésionnelle
US20140142861A1 (en) 2010-11-06 2014-05-22 Oklahoma Medical Research Foundation Biomarkers For Predicting Progressive Joint Damage
CN102321574B (zh) * 2011-08-10 2012-11-21 郭风劲 Xbp1s，一种新型促进软骨修复的转录因子
WO2015015000A1 (fr) 2013-08-02 2015-02-05 Université Catholique de Louvain Signature d'hypoxie cyclique et son utilisation pour le pronostic du cancer
CA2922143C (fr) 2013-09-12 2022-03-08 Rush University Medical Center Repertoire de transcriptome pour la caracterisation de reponse de reparation cellulaire apres blessure des tissus mous dans des articulations synoviales
US20190093166A1 (en) 2016-03-04 2019-03-28 Rush University Medical Center Methods for characterizing the cellular repair response after soft tissue injury

Also Published As

Publication number Publication date
ES2756173T3 (es) 2020-04-27
CN105531378A (zh) 2016-04-27
CN105531378B (zh) 2021-04-09
US20180291455A1 (en) 2018-10-11
US12297500B2 (en) 2025-05-13
US9994903B2 (en) 2018-06-12
WO2015038474A1 (fr) 2015-03-19
CA2922143A1 (fr) 2015-03-19
US20160215342A1 (en) 2016-07-28
EP3044336B1 (fr) 2019-11-06
EP3044336A4 (fr) 2017-04-19
EP3044336A1 (fr) 2016-07-20

Similar Documents

Publication Publication Date Title
US20190137495A1 (en) Method of Predicting Personalized Response to Cancer Therapy, Method of Treating Cancer, and Kit Therefor
Chen et al. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis
CA2922143C (fr) Repertoire de transcriptome pour la caracterisation de reponse de reparation cellulaire apres blessure des tissus mous dans des articulations synoviales
Arthur et al. EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair
WO2011117366A3 (fr) Gènes et combinaisons de gènes prédictifs d'une réponse précoce ou d'une non-réponse de sujets souffrant d'une maladie inflammatoire à des médicaments ciblant les cytokines (cytd)
JP2019516979A (ja) 固形腫瘍を有する患者をクラス分けするための方法
US20220018835A1 (en) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
Tural et al. Association between osteoporosis and polymorphisms of the IL-10 and TGF-beta genes in Turkish postmenopausal women
Pola et al. Interleukin-6 gene polymorphism and risk of osteoarthritis of the hip: a case–control study
EP3254697A1 (fr) Des moyens pour le traitement de la guérison d'une fracture retardée
Lucendo Cellular and molecular immunological mechanisms in eosinophilic esophagitis: an updated overview of their clinical implications
WO2012101183A3 (fr) Gènes et combinaisons de gènes basés sur le gène mknk1 prédictifs de réponse précoce ou de non-réponse de sujets souffrant de maladie inflammatoire à des médicaments ciblant les cytokines (cytd) ou des médicaments biologiques anti-inflammatoires
Lin et al. The mandibular cartilage metabolism is altered by damaged subchondral bone from traumatic impact loading
CN114651071A (zh) 用于确定患者发生卫生护理相关感染的风险的方法
JP2011109929A (ja) 関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
RU2796885C1 (ru) Способ прогнозирования риска клинически значимого снижения контроля бронхиальной астмы в сезон с низкой температурой воздуха
US20240390463A1 (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
Prodan Impact of GHRL (RS696217) and LEPR (RS1137101) gene polymorphisms on hormonal and anthropometric outcomes after bariatric surgery
Hernandez-Molina et al. THU0221 DRY EYE IN SJÖGREN'S SYNDROME: CHEMOKINE AND CYTOKINE TEAR SPECTRUM
Srivastava et al. The effect of letrozole on endometriosis MD-E cell line gene expression
Wieser et al. Presence of chronic fatigue syndrome in endometriosis is associated with increased psychological stress and reduced cortisol levels
Kume et al. THU0109 Treating to target ultrasound with clinical remission better effects than clinical remission in RRP
Nicolai et al. THU0507 TYPE I INTERFERON SCORE AND INTERFERON INDUCED MEDIATORS CXCL10 AND NEOPTERIN ARE CORRELATED WITH DISEASE ACTIVITY IN JUVENILE DERMATOMYOSITIS
Manzo et al. AB0263 Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs
Hillen et al. THU0222 PLASMACYTOID DCS FROM PATIENTS WITH SJÖGREN'S SYNDROME ARE TRANSCRIPTIONALLY PRIMED FOR ENHANCED PRO-INFLAMMATORY CYTOKINE PRODUCTION

Legal Events

Date Code Title Description
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240830

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240830

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829